Patients received either bevacizumab ( 7.5 mg/kg ) + XELOX ( capecitabine 1,000 mg/m ( 2 ) twice daily on days 1-14 + oxaliplatin 130 mg/m ( 2 ) on day 1 every 3 weeks ) until disease progression ( arm A ) or the same doses of bevacizumab + XELOX for 6 cycles followed by bevacizumab + capecitabine until disease progression ( arm B ) .